SCHEMBL8558105

SCHEMBL8558105

Cc1cc(OCc2ccccc2)nc(S(C)(=O)=O)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 6/20 0.44
NUDT1 P36639 1/20 0.44
TSHR P16473 5/20 0.43
LMNA P02545 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
HPGD P15428 2/20 0.41
GLA P06280 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NPC1 O15118 1/20 0.40
AR P10275 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8559618 0.86 NUDT1 (0.44) ALDH1A1SMN1; SMN2NUDT1LMNAL3MBTL1
SCHEMBL8558749 0.86 NUDT1 (0.44) SMN1; SMN2NUDT1LMNAHPGDPOLB
SCHEMBL18689703 0.85 PDE2A (0.51) ALDH1A1KMT2ASMN1; SMN2LMNAL3MBTL1
SCHEMBL8562901 0.84 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2NUDT1LMNAHPGD
SCHEMBL8560362 0.81 SDHB (0.56) ALDH1A1KMT2ASMN1; SMN2LMNAKDM4E
SCHEMBL3543675 0.79 ALKBH1 (0.44) SMN1; SMN2NUDT1L3MBTL1HPGDMAPT
SCHEMBL8869963 0.79 LMNA (0.50) ALDH1A1KMT2ASMN1; SMN2NUDT1LMNA
SCHEMBL8667528 0.78 MAPT (0.56) ALDH1A1KMT2ASMN1; SMN2TSHRLMNA
SCHEMBL1564355 0.77 ALDH1A1 (0.64) ALDH1A1KMT2ASMN1; SMN2NUDT1TSHR
SCHEMBL26840293 0.77 ALDH1A1 (0.50) ALDH1A1KMT2ASMN1; SMN2NUDT1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313554-A1 PTPN2 INHIBITORS MONDEGO BIO, LDA. (PT) 2025-10-09 US disclosed
EP-4522594-A1 PTPN2 INHIBITORS Ness Therapeutics, Inc. (US) 2025-03-19 EP disclosed
CN-119522216-A PTPN2 inhibitors 尼斯治疗公司 2025-02-25 CN disclosed
WO-2023220572-A1 PTPN2 INHIBITORS NESS THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
US-5726128-A Benzyloxypyrimidine derivative, processes for producing the same and herbicidal composition KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1998-03-10 US disclosed
EP-0707001-A1 Benzyloxypyrimidine derivative, processes for producing the same and herbicidal composition KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1996-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313554-A1 PTPN2 INHIBITORS PTPN2, PTPN1, PTPRJ ALDH1A1 3498/4885KMT2A 1912/4885SMN1; SMN2 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.